FPI-2620 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 127 | Frontotemporal lobar degeneration | 1 |
127. Frontotemporal lobar degeneration
Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05456503 (ClinicalTrials.gov) | September 19, 2022 | 8/7/2022 | PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620 | Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand PI-2620 | Frontotemporal Lobar Degeneration;Alzheimer Disease;Cognitively Normal | Drug: FPI-2620 | University of Pennsylvania | National Institutes of Health (NIH) | Recruiting | 45 Years | N/A | All | 54 | Phase 3 | United States |